1. Home
  2. SPRO vs GAUZ Comparison

SPRO vs GAUZ Comparison

Compare SPRO & GAUZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • GAUZ
  • Stock Information
  • Founded
  • SPRO 2013
  • GAUZ 2009
  • Country
  • SPRO United States
  • GAUZ Israel
  • Employees
  • SPRO N/A
  • GAUZ N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • GAUZ Industrial Machinery/Components
  • Sector
  • SPRO Health Care
  • GAUZ Miscellaneous
  • Exchange
  • SPRO Nasdaq
  • GAUZ Nasdaq
  • Market Cap
  • SPRO 121.0M
  • GAUZ 102.0M
  • IPO Year
  • SPRO 2017
  • GAUZ 2024
  • Fundamental
  • Price
  • SPRO $1.90
  • GAUZ $5.72
  • Analyst Decision
  • SPRO Buy
  • GAUZ Strong Buy
  • Analyst Count
  • SPRO 4
  • GAUZ 3
  • Target Price
  • SPRO $5.00
  • GAUZ $13.67
  • AVG Volume (30 Days)
  • SPRO 391.2K
  • GAUZ 62.8K
  • Earning Date
  • SPRO 08-12-2025
  • GAUZ 11-11-2025
  • Dividend Yield
  • SPRO N/A
  • GAUZ N/A
  • EPS Growth
  • SPRO N/A
  • GAUZ N/A
  • EPS
  • SPRO N/A
  • GAUZ N/A
  • Revenue
  • SPRO $48,576,000.00
  • GAUZ $96,810,000.00
  • Revenue This Year
  • SPRO N/A
  • GAUZ $23.16
  • Revenue Next Year
  • SPRO N/A
  • GAUZ $40.82
  • P/E Ratio
  • SPRO N/A
  • GAUZ N/A
  • Revenue Growth
  • SPRO N/A
  • GAUZ 7.87
  • 52 Week Low
  • SPRO $0.51
  • GAUZ $4.54
  • 52 Week High
  • SPRO $3.22
  • GAUZ $13.00
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 39.50
  • GAUZ 50.06
  • Support Level
  • SPRO $1.91
  • GAUZ $5.19
  • Resistance Level
  • SPRO $2.18
  • GAUZ $5.23
  • Average True Range (ATR)
  • SPRO 0.10
  • GAUZ 0.32
  • MACD
  • SPRO 0.01
  • GAUZ 0.09
  • Stochastic Oscillator
  • SPRO 19.18
  • GAUZ 80.82

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About GAUZ Gauzy Ltd. Ordinary Shares

Gauzy Ltd is a fully integrated light and vision control company. Its products include suspended particle device and liquid crystal materials for smart glass applications and AI-powered driver assistance systems, or ADAS, solutions including camera monitoring systems. The company's operating segments are Architecture, Automotive, Safety tech, and Aeronautics. Maximum revenue is generated from its Safety tech segment, which focuses on sales of driver assistance systems for buses, coaches, recreational vehicles, and specific vehicles, such as camera and motion sensor systems, smart mirrors, and safety doors. Geographically, it derives maximum revenue from other European countries (excluding France), followed by the United States, France, Asia, Israel, and other regions.

Share on Social Networks: